BioNTech’s mRNA Cancer Vaccine Has Started Phase 2 Clinical Trial

Colorectal cancer was chosen by BioNTech as an experimental vaccine target due to the disease’s relatively high relapse rate.

Via


Send to Facebook | Send To Twitter
  • Twitch

     

  • Leave A Comment

    Subscribe
    Notify of
    0 Comments
    Inline Feedbacks
    View all comments
  • Here's a few awesome images!